Results 181 to 190 of about 299,767 (358)
Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model. [PDF]
Ndumnego OC +4 more
europepmc +1 more source
Immune sera and antiglycoprotein monoclonal antibodies inhibit in vitro cell-to-cell spread of pathogenic rabies viruses [PDF]
D L Lodmell, L C Ewalt
openalex +1 more source
A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti +3 more
wiley +1 more source
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg +43 more
wiley +1 more source
Dengue immune sera enhance Zika virus infection in human peripheral blood monocytes through Fc gamma receptors. [PDF]
Li M +10 more
europepmc +1 more source
Sera and the in Vitro Induction of Immune Responses [PDF]
Stanley M. Shiigi, Robert I. Mishell
openalex +1 more source
Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken +7 more
wiley +1 more source
Quantitation of Antibodies in the Sera of Immunodeficient Patients Receiving Monthly Intravenous Immune Globulin (IVIg) [PDF]
Maura Pieretti +1 more
openalex +1 more source

